# Postop Pain Management in Pituitary Tumour Patients

> **NCT06353529** · PHASE4 · RECRUITING · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 108 (estimated)

## Conditions studied

- Pituitary
- Pain, Postoperative

## Interventions

- **DRUG:** Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
- **DRUG:** Placebo
- **DRUG:** Sham Comparator

## Key facts

- **NCT ID:** NCT06353529
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2026-04
- **Final completion:** 2026-07
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06353529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06353529, "Postop Pain Management in Pituitary Tumour Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06353529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*